Dupilumab tied to low serious infection risk, increase in conjunctivitis in AD patients
Treatment with dupilumab confers a low risk of serious infections in patients with atopic dermatitis (AD) but is associated with a clinically meaningful increase in conjunctivitis that requires management in practice, suggest the results of a recent study.
Dupilumab tied to low serious infection risk, increase in conjunctivitis in AD patients
07 Feb 2021
